Tamsulosin Hydrochoride

We present the fourth reported case of tamsulosin induced priapism in an elderly gentleman with diabetes and hypertension in whom penile blood gas analysis revealed IP. Intracavernous phenylephrine injection relieved IP. Subsequent cardiac monitoring revealed ST segment depression and positive troponins confirming a diagnosis of NSTEMI which was managed by PCI and medical therapy.

We evaluate the efficacy and safety of tamsulosin a selective alpha(1A)-receptor antagonist in patients with painful ejaculation (PE) as a sole entity. A total of 118 men with PE were included in the study. Patients were randomly assigned to receive 0.4 mg oral daily tamsulosin (group 1, n=59) or placebo (group 2, n=59), during a 6-week period for each agent. Pretreatment evaluation included history and physical examination, International Index of Erectile Function (IIEF) and a visual analog scale (VAS) for pain. The efficacy of two treatments was assessed every 2 weeks during treatment, and at the end of the study using responses to IIEF, VAS evaluation, mean intercourse satisfaction domain, mean weekly coitus episodes and adverse drug effects. In all, 104 patients (88%) completed the whole treatment schedule. Pain resolved in 16 and 13% of the patients treated with tamsulosin and placebo, respectively (P=0.1). Baseline mean intercourse satisfaction domain values of IIEF 10 and 11 reached to 12 and 10 at 6-week treatment in groups 1 and 2, respectively (P=0.08). The VAS after tamsulosin and placebo decreased from 5.7 and 5.8 to 5.1 and 5.5, respectively (P=0.1). The mean weekly intercourse episodes increased from pretreatment values of 1.8 and 1.6 to 1.9 and 1.7, for tamsulosin and placebo, respectively (P=0.08). Mean number of adverse events was 11 for tamsulosin and 5 for placebo (P<0.05). Tamsulosin is no better than placebo in improvement of PE as a sole entity.

We evaluate the efficacy and safety of tamsulosin a selective alpha(1A)-receptor antagonist in patients with painful ejaculation (PE) as a sole entity. A total of 118 men with PE were included in the study. Patients were randomly assigned to receive 0.4 mg oral daily tamsulosin (group 1, n=59) or placebo (group 2, n=59), during a 6-week period for each agent. Pretreatment evaluation included history and physical examination, International Index of Erectile Function (IIEF) and a visual analog scale (VAS) for pain. The efficacy of two treatments was assessed every 2 weeks during treatment, and at the end of the study using responses to IIEF, VAS evaluation, mean intercourse satisfaction domain, mean weekly coitus episodes and adverse drug effects. In all, 104 patients (88%) completed the whole treatment schedule. Pain resolved in 16 and 13% of the patients treated with tamsulosin and placebo, respectively (P=0.1). Baseline mean intercourse satisfaction domain values of IIEF 10 and 11 reached to 12 and 10 at 6-week treatment in groups 1 and 2, respectively (P=0.08). The VAS after tamsulosin and placebo decreased from 5.7 and 5.8 to 5.1 and 5.5, respectively (P=0.1). The mean weekly intercourse episodes increased from pretreatment values of 1.8 and 1.6 to 1.9 and 1.7, for tamsulosin and placebo, respectively (P=0.08). Mean number of adverse events was 11 for tamsulosin and 5 for placebo (P<0.05). Tamsulosin is no better than placebo in improvement of PE as a sole entity.

The use of tamsulosin caused a significantly more frequent (in 85.71 % versus 70.31 % of patients on conventional lithokinetic therapy) and earlier discharge of distal ureteral calculi. No side effects were observed.
--
При применении «Тамсулона-ФС» (тамсулозина) отмечено достоверно более частое отхождение камней дистального отдела мочеточника (на 15 % по сравнению с показателями при традиционной литокинетической терапии) и в более короткие сроки. Побочных эффектов не отмечено.

The objective of this study was to determine the effect of administration of tamsulosin on oral glucose tolerance in normal Wistar rats. Forty (40) male albino Wistar rats were selected and divided into four (4) groups of ten (10) rats each, viz, GROUP I, II, III and IV. Group I (Normal control): Distilled water (5ml/kg), Group II (Positive control): Carvedilol(800µg/kg), Group III (Tamsulosin treated): Tamsulosin (12µg/kg), Group IV (Tamsulosin treated): Tamsulosin (40µg/kg).Different treatments of Distilled water, Carvedilol and Tamsulosin were administered once every day orally for the period of six (6) weeks. After the 6th week of the study, all the treatments were withdrawn for a further 2 weeks (7th and 8th weeks). The Animals underwent 8 hours fasting. OGTT was done at baseline (0th), and then at3rd, 6th, 7thand 8th weeks. The blood glucose of all the animals was measured via tip tail incision at 0hours (pre-glucose load). Then, 2g/kg of D(+)-glucose powder dissolved in distilled water was administered to all the animals orally; after which blood samples were measured via tail tip incision at 30, 60 and 120 minutes using standard glucometer. ANOVA and Tukey Kramer post hoc test was used. The results were revealed therein. At the baseline of the study, 2nd, 3rd week, the groups of rats treated with carvedilol (positive control),tamsulosin high dose (40µg/kg) or low dose (12µg/kg) did not show any significant difference (P>0.05) in total area under the oral glucose tolerance curve compared to the normal control group and other inter group comparison. At the 6th week of the study, the group of rats treated with carvedilol (positive control), tamsulosin low dose (12µg/kg) and tamsulosin high dose (40µg/kg) revealed significantly higher values (P<0.05) of total area under the oral glucose tolerance curve compared to the normal control group. Other inter-group comparisons were not significantly different (P>0.05). At the 7th week of the study, the group of rats treated with carvedilol (positive control), tamsulosin low dose (12µg/kg) and tamsulosin high dose (40µg/kg) revealed no significant differences (P>0.05) in total area under the oral glucose tolerance curve compared to normal control group and other inter-groups comparison. At the 8th week of the study (two weeks after treatments withdrawal), only group of rats treated with carvedilol (positive control) revealed significantly higher values (P<0.05) of total area under the oral glucose tolerance curve than the normal control group. Other inter-group comparisons were not significantly different. The current study revealed that tamsulosin affects the glucose tolerance of the Wistar rats, thereby causing hyperglycemia.